Pharmacutical Recombinant Therapeutic Antibodies | 页面 2

REPORT DESCRIPTION
Recombinant Therapeutic Antibodies and Proteins Market : Overview
Therapeutic proteins are engineered in the laboratory for pharmaceutical use,
including non-covalent binders. These proteins are highly effective and serve as
modernized treatment for rare as well as chronic diseases. Protein therapeutics offer
custom-made treatment approach by supporting a specifically targeted therapeutic
process by compensating the deficiency of an essential protein. Recombinant
proteins have gained significant traction for therapeutic applications and the number
of proteins either launched or approved into clinical trials has continually increased
over the past two decades. According to the National Center for Biotechnology
Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA)
approved over 140 recombinant therapeutic proteins for human use and several
hundred are currently in development. Majority of these proteins are recombinant
monoclonal antibodies.
The global recombinant therapeutic antibodies and proteins market size was valued
at US$ 91.2 billion in 2017, and is expected to witness a robust CAGR of 12.2%
over the forecast period (2018 – 2026).
© Coherent market Insights. All Rights Reserved